Send this resource to your team or professional network.
Editorial hold: Draft for future publication. Evidence checked October 6, 2026. Keep unpublished until Canadian approval and a review of the claims against the evidence available then.
The interest in retatrutide comes from real clinical findings: substantial weight loss, lower liver fat, better blood sugar readings and improvements in some obesity-related conditions.
If you are considering switching to retatrutide from tirzepatide or semaglutide, those findings deserve a closer look. Here are ten reasons to discuss its potential with your prescriber if it becomes an approved option for you.
The evidence boundary: these are observed benefits and research findings, not proof that switching will improve your results. Retatrutide remains investigational. The studies below cannot tell you how much extra weight you would lose after changing medicines. Trial doses identify study groups; they are not dosing instructions.
Laboratory references: See the Retatrutide research peptide product page for material specifications and the batch COA reports for analytical documentation. These are laboratory references, not products for switching prescribed treatment.
1. Retatrutide weight loss results show substantial reductions
Lilly’s May 2026 TRIUMPH-1 report put average weight loss at 28.3% after 80 weeks in the 12 mg group, versus 2.2% with placebo. Participants had obesity or overweight with a related condition, without diabetes.
That analysis estimated outcomes if participants stayed on treatment without prohibited weight-management treatments. An analysis including treatment discontinuation and other treatment changes reported 25.0%, versus 3.9% with placebo. Both figures matter when reading retatrutide results. Source: Lilly’s TRIUMPH-1 announcement.
2. Some participants kept losing weight beyond 80 weeks
In a selected TRIUMPH-1 extension group, participants continuing from the 12 mg arm reached average weight loss of 30.3% at 104 weeks. This was total loss from baseline, not another 30.3%.
The extension included people with a starting BMI of at least 35 who had completed the main study and tolerated treatment. It suggests sustained benefit in that selected group, not a proven solution for a plateau on another medicine. Source: TRIUMPH-1 extension results.
3. It brings a third hormone target into the picture
Semaglutide acts on GLP-1 receptors. Tirzepatide acts on GLP-1 and GIP receptors. Retatrutide adds the glucagon receptor.
Researchers call this a triple agonist. In simple terms, it acts on three hormone-signalling systems involved in metabolism. This gives researchers a different approach to study; the receptor count alone does not prove better results. Source: the original retatrutide obesity trial.
Our tirzepatide vs retatrutide comparison explains the difference in more detail.
4. Researchers measured a large reduction in liver fat
In a 98-person study of fatty liver disease, also called MASLD, the 12 mg retatrutide group had an average 82.4% relative reduction in liver fat at 24 weeks. The placebo group had a 0.3% increase.
Researchers measured fat using MRI. This is a promising liver-fat finding, not proof of an 82.4% reduction in liver disease or reversal of liver scarring. Source: Nature Medicine liver-fat study.
5. The research also shows less fat around abdominal organs
Visceral fat sits deep inside the abdomen, around organs. In the same study, researchers measured reductions in this fat across retatrutide groups.
At 48 weeks, average reductions ranged from 16.1% to 48.3% across doses, compared with a 2.5% increase with placebo. These were findings from a small, selected study; they do not establish better visceral-fat loss than semaglutide or tirzepatide. Source: the study’s abdominal-fat measurements.
6. Blood sugar improved in people with type 2 diabetes
Weight is only one part of diabetes care. A1C, which reflects average blood sugar over recent months, matters too.
In its September 2026 TRIUMPH-2 announcement, Lilly reported average A1C reductions of up to 1.6 percentage points, alongside weight loss. The trial studied adults with type 2 diabetes and obesity or overweight.
This supports interest in retatrutide’s metabolic effects. It does not establish that replacing your current diabetes medicine would improve your control. Source: Lilly’s TRIUMPH-2 report.
7. Blood pressure and blood-fat markers improved
Lilly reported TRIUMPH-1 reductions from baseline of up to 12.3 mmHg in systolic blood pressure, 41.0% in triglycerides and 24.2% in non-HDL cholesterol at 80 weeks. These are risk-marker changes, not proof of fewer heart attacks. Source: Lilly’s June 2026 report.
8. Participants with knee osteoarthritis reported less pain
In the TRIUMPH-1 knee-pain substudy, Lilly reported improvement of up to 4.3 points on the WOMAC pain scale at 80 weeks. That is evidence about pain, not proof that retatrutide repairs cartilage. Source: TRIUMPH-1 knee-pain findings.
9. Sleep-apnoea severity fell in a clinical substudy
For participants with moderate-to-severe obstructive sleep apnoea, Lilly reported reductions of up to 36.1 breathing events per hour at 80 weeks. These findings do not justify stopping CPAP or other prescribed treatment. Source: TRIUMPH-1 sleep-apnoea findings.
Figures in sections 7-9 are sponsor-reported changes from baseline using the efficacy analysis; they are not placebo-adjusted differences or comparisons with semaglutide or tirzepatide.
10. Body scans confirm that fat loss contributes to the results
Scale weight alone cannot tell you what changed. A Phase 2 body-composition substudy in people with type 2 diabetes used scans to separate changes in fat and lean mass.
Researchers found greater fat-mass reduction than lean-mass loss. That supports a body-fat benefit, but participants also lost lean mass. Retatrutide does not have evidence here for preventing muscle loss or preserving more muscle than semaglutide or tirzepatide. Source: the body-composition substudy.
If you discuss a future treatment change, include strength, nutrition and daily function in your goals. Our GLP-1 food, side-effect and muscle-health guide covers those questions.
Retatrutide side effects belong in the decision
Benefits need to be weighed against risks. The Phase 2 obesity trial reported digestive side effects and dose-related increases in heart rate. Increases peaked at 24 weeks and then declined. Read the trial’s safety findings.
Current evidence does not support promising fewer side effects, a reliable plateau breakthrough, or a safe self-directed conversion from another medicine.
Switching to retatrutide: common questions
Is retatrutide better than semaglutide or tirzepatide?
The studies above show benefits in their own participants. They do not establish ten advantages over either medicine. Differences between tirzepatide and retatrutide studies, including populations, durations and analysis methods, make headline percentages unsuitable for a direct ranking.
Retatrutide vs Mounjaro: what comparison matters?
Mounjaro contains tirzepatide. Researchers are comparing retatrutide with tirzepatide in TRIUMPH-5. Its registry had no posted results at our October 6, 2026 check. It is not a trial of an immediate switch from ongoing treatment. See TRIUMPH-5.
Does this mean I should change my treatment now?
No. Retatrutide remains investigational. Keep treatment decisions with your prescriber, and do not substitute online research products for prescribed medicines. Check its current status.
For more context, read our comparison of tirzepatide and retatrutide research. If approval comes, the decision to switch should depend on the authorized use, the latest comparative evidence and your own medical needs.
Laboratory product references and batch documentation
For laboratory researchers comparing material specifications, Anglo Peptides lists retatrutide research material, tirzepatide research material and semaglutide research material. These catalogue links describe laboratory products, not approved treatment options or products for making a medication switch.
Use the batch certificate of analysis page to request the analytical documentation for a specific lot. A purity report does not establish clinical equivalence, sterility or suitability for human use.
Explore the peptide research library for related studies, evidence guides and laboratory resources.
